Plus Therapeutics, Inc. (PSTV) Financial Ratios
28 years of historical data (1998–2025) · Healthcare · Biotechnology
EV/EBITDA
N/A
—
5yr avg: N/A
P/FCF
N/A
—
5yr avg: N/A
P/B Ratio
↑
3.27
-2% vs avg
5yr avg: 3.33
30Y Low0.0·High17.8
ROE
↓
-560.2%
↑-48% vs avg
5yr avg: -377.7%
30Y Low-394%·High-15%
Debt/EBITDA
N/A
—
5yr avg: N/A
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
PSTV Valuation Multiples
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
Plus Therapeutics, Inc. currently has a negative P/E ratio, indicating the company is operating at a loss on a trailing-twelve-month basis.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $10M | $40M | $9M | $5513 | $8400 | $12600 | $9090 | $3600 | — | $956250 | $196M |
| Enterprise Value | $2M | $32M | $12M | $-4367488 | $-12356600 | $-11394400 | $-1340910 | $-5575400 | — | $5M | $201M |
| P/E Ratio → | -0.58 | — | — | — | — | — | — | — | — | — | — |
| P/S Ratio | 1.95 | 7.65 | 1.52 | 0.00 | 0.04 | — | 0.03 | 0.00 | — | 0.15 | 17.22 |
| P/B Ratio | 3.27 | 9.98 | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.01 | 0.07 | 17.82 |
| P/FCF | — | — | — | — | — | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
PSTV EV Ratios
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 6.13 | 2.09 | -0.89 | -55.16 | — | -4.43 | -0.80 | — | 0.78 | 17.66 |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — | — | — | — | — | — |
PSTV Profitability
Margins and return-on-capital ratios measuring operating efficiency
Plus Therapeutics, Inc. earns an operating margin of -293.5%. Operating margins have compressed from -271.1% to -293.5% over the past 3 years, signaling potential cost pressures or competitive headwinds. A negative ROE of -560.2% indicates the company is currently destroying shareholder equity.
Margins
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 91.5% | 91.5% | 85.4% | -97.2% | -217.9% | — | -791.1% | 100.0% | 61.5% | 79.4% | 76.1% |
| Operating Margin | -293.5% | -293.5% | -252.3% | -271.1% | -8800.0% | — | -3163.0% | -52.3% | -293.7% | -322.6% | -173.2% |
| Net Profit Margin | -429.4% | -429.4% | -222.8% | -271.0% | -9051.3% | — | -2719.8% | -155.6% | -423.5% | -353.9% | -193.7% |
Return on Capital
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -560.2% | -560.2% | — | -522.5% | -234.7% | -193.3% | -393.3% | -341.0% | -138.6% | -189.2% | -190.1% |
| ROA | -195.0% | -195.0% | -144.0% | -75.5% | -88.4% | -78.6% | -46.6% | -46.1% | -45.4% | -68.5% | -61.0% |
| ROIC | — | — | — | — | — | -1688.1% | — | -56.3% | -42.1% | -93.6% | -96.6% |
| ROCE | -381.4% | -381.4% | — | -210.2% | -140.2% | -127.0% | -155.7% | -48.2% | -89.3% | -117.2% | -76.7% |
PSTV Leverage & Debt
Solvency and debt-coverage ratios — lower is generally safer
The company holds a net cash position — cash of $9M exceeds total debt of $821000, providing substantial financial flexibility for buybacks, acquisitions, or weathering downturns.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.21 | 0.21 | — | — | 0.89 | 0.65 | 2.31 | 10.32 | 2.72 | 1.05 | 1.61 |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Net Debt / Equity | — | -1.99 | — | — | -1.92 | -1.05 | -0.45 | -4.81 | 1.71 | 0.31 | 0.46 |
| Net Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Debt / FCF | — | — | — | — | — | — | — | — | — | — | — |
| Interest Coverage | -4.24 | -4.24 | -2.48 | -33.72 | -27.52 | -13.38 | -7.95 | -0.77 | -3.62 | -10.07 | -7.51 |
Net cash position: cash ($9M) exceeds total debt ($821000)
PSTV Liquidity & Efficiency
Short-term solvency ratios and asset-utilisation metrics
A current ratio of 1.23x means Plus Therapeutics, Inc. can comfortably meet its short-term obligations, though there is limited excess liquidity. The current ratio has improved from 0.92x to 1.23x over the past 3 years.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 1.23 | 1.23 | 0.34 | 0.92 | 1.84 | 3.36 | 1.07 | 1.37 | 0.55 | 0.81 | 1.50 |
| Quick Ratio | 1.23 | 1.23 | 0.34 | 0.92 | 1.84 | 3.36 | 1.07 | 1.36 | 0.54 | 0.63 | 1.20 |
| Cash Ratio | 0.71 | 0.71 | 0.23 | 0.80 | 1.53 | 3.13 | 0.98 | 1.21 | 0.30 | 0.52 | 1.00 |
| Asset Turnover | — | 0.32 | 0.88 | 0.43 | 0.01 | — | 0.03 | 0.30 | 0.12 | 0.20 | 0.33 |
| Inventory Turnover | — | — | — | — | — | — | — | — | 10.73 | 0.41 | 0.73 |
| Days Sales Outstanding | — | — | 35.79 | — | — | — | 71.07 | 68.48 | 28.51 | 14.63 | 41.47 |
PSTV Shareholder Yields
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Plus Therapeutics, Inc. does not currently pay a dividend and has no material buyback yield, reinvesting earnings back into the business.
Dividends
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — | — |
Total Shareholder Return Metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 4.2% | 100.0% | 0.0% | 0.0% | 0.0% | 0.0% | — | 100.0% | 0.0% |
| Total Shareholder Yield | 0.0% | 0.0% | 4.2% | 100.0% | 0.0% | 0.0% | 0.0% | 0.0% | — | 100.0% | 0.0% |
| Shares Outstanding | — | $3M | $308030 | $126 | $70 | $32 | $12 | $4 | $0 | $17 | $692 |
Peer Comparison
Compare PSTV with 10 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
 PSTVYou | $10M | -0.6 | — | — | 91.5% | -293.5% | -560.2% | — | — |
 NRXP | $69M | -3.0 | — | — | 58.8% | -1324.4% | — | — | — |
 AGEN | $125M | -882.4 | — | — | 29.6% | -18.0% | — | — | — |
 CLDX | $2B | -8.3 | — | — | 100.0% | -19160.0% | -40.6% | -35.2% | — |
 IART | $1B | -2.6 | 14.4 | — | 51.7% | 4.2% | -39.9% | 1.7% | 9.3 |
 ACTG | $469M | 22.1 | 5.3 | 8.0 | 82.5% | 2.2% | 3.8% | 1.2% | 2.0 |
 NVCR | $2B | -11.7 | — | — | 74.5% | -23.5% | -38.9% | -16.4% | — |
 ARAY | $41M | -22.4 | 11.5 | — | 32.1% | 1.7% | -2.5% | 3.0% | 12.6 |
 BNGO | $4M | -0.2 | — | — | 22.0% | -116.9% | -66.2% | -49.1% | — |
 NVS | $281B | 20.5 | 13.7 | 15.9 | 75.0% | 31.2% | 31.0% | 18.8% | 1.7 |
 ISRG | $144B | 51.7 | 39.0 | 58.0 | 66.0% | 29.3% | 16.6% | 15.0% | 0.1 |
| Healthcare Median | — | 22.1 | 14.2 | 18.5 | 63.9% | -4.3% | -32.6% | -11.6% | 3.2 |
Peer selection based on competitive and market overlap. Compare multiple stocks →
Download Financial Ratios Data
Includes 30+ ratios · 28 years · Updated daily
Consensus-Based Analysis Tools
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Check Valuation
Historical Returns
10-year return with dividends reinvested.
Calculate
DCA Calculator
See how regular investing compounds over time.
Run Numbers
Peer Comparison
Compare growth, multiples, and margins vs sector.
Compare
PSTV — Frequently Asked Questions
Quick answers to the most common questions about buying PSTV stock.
What is Plus Therapeutics, Inc.'s P/E ratio?
Plus Therapeutics, Inc.'s current P/E ratio is -0.6x. This places it at the 50th percentile of its historical range.
What is Plus Therapeutics, Inc.'s ROE?
Plus Therapeutics, Inc.'s return on equity (ROE) is -560.2%. The historical average is -181.6%.
Is PSTV stock overvalued?
Based on historical data, Plus Therapeutics, Inc. is trading at a P/E of -0.6x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
What are Plus Therapeutics, Inc.'s profit margins?
Plus Therapeutics, Inc. has 91.5% gross margin and -293.5% operating margin.